CHRONIC MYOCARDITIS IN A COXSACKIE VIRUS MURINE MODEL

柯萨奇病毒鼠模型中的慢性心肌炎

基本信息

项目摘要

The goals of this proposal are to identify mechanisms by which a small nonenveloped RNA genome virus induces severe focal inflammation in heart tissues of mice, as a model of human disease myocarditis. Most human patients with chronic myocarditis produce autoantibodies to antigens on cardiac tissue. In a murine model of coxsackievirus B3 (CVB3)-induced chronic myocarditis, autoantibodies are also produced against cardiac cell antigens. Administration of murine sera containing CVB3-neutralizing antibodies into CVB3-inoculated mice at 3 days post-inoculation exacerbates myocarditis, suggesting the presence of pathologic antibodies. Preliminary studies of neutralizing monoclonal antibodies (mAbs) against CVB3 demonstrate shared epitopes between CVB3 particles and cultured murine cardiac fibroblasts, as assessed by antibody binding studies, complement- mediated lysis of fibroblasts and stimulation of synthesis of a macrophage chemoattractant by fibroblasts. One mAb induces myocarditis in normal mice. Mechanisms by which eight mAbs could contribute to pathogenesis of myocarditis in mice will be identified. Induction of myocarditis by mAB will be confirmed. The capacity of mAbs for participating in complement- or killer cell-mediated lysis of murine cardiac fibroblasts will be quantitatively assessed. mAb-enhanced production of soluble factors from cardiac fibroblasts will be quantified. The viral polypeptide(s) to which the eight mAbs bind will be identified. Several laboratories have shown that enteroviral genomes are present in heart tissues of 15-25% of patients with myocarditis when infectious virus cannot be detected. CVB3 murine models of chronic myocarditis will be used to determine whether viral genomes persist in heart tissues, using in situ transcription and polymerase chain reaction. To understand the molecular basis of CVB3- induced myocarditis, the genomes of highly myocarditic (CVB3m) and amyocarditic (CVB3o) variants will be cloned. Reciprocal recombinant viruses will be generated by construction of hybrid genomes from infectious cDNA molecules of each genome and assessed for myocarditis-inducing ability in adolescent mice. Infectious hybrid cDNA molecules will be constructed with progressively smaller nucleotide regions associated with myocarditis to generate recombinant viruses. The nucleotide regions associated with myocarditis will be sequenced. CVB3 infection of some murine strains induces T cells which lyse uninfected target cells. Experiments will determine whether T lymphocytes from CVB3m-inoculated mice with chronic myocarditis will proliferate in vitro in response to soluble antigens extracted from normal murine hearts/cultured cardiac fibroblasts and whether extent of proliferation is predictive of severity of myocarditis.
本建议的目标是确定一个小的 无包膜RNA基因组病毒引起严重的心脏局灶性炎症 小鼠组织,作为人类疾病心肌炎的模型。 大多数人类 慢性心肌炎患者产生自身抗体, 心脏组织 在柯萨奇病毒B3(CVB 3)诱导的小鼠模型中, 慢性心肌炎,自身抗体也产生对心脏细胞 抗原 施用含有CVB 3中和的鼠血清 在接种后3天将抗体注入接种CVB 3的小鼠, 心肌炎,表明存在病理性抗体。 初步 抗CVB 3中和性单克隆抗体的研究 证实了CVB 3颗粒和培养的小鼠之间的共有表位 心脏成纤维细胞,如通过抗体结合研究评估的,补体- 介导的成纤维细胞溶解和巨噬细胞合成的刺激 成纤维细胞的化学引诱物。 一种mAb诱导正常人心肌炎 小鼠 八种mAb可能有助于发病机制的机制 将鉴定小鼠的心肌炎。 单克隆抗体诱发心肌炎 将得到证实。 mAb参与补体的能力- 或杀伤细胞介导的鼠心脏成纤维细胞裂解将被 定量评估。 mAb增强的可溶性因子的产生来自 将对心脏成纤维细胞进行定量。 所述病毒多肽, 将鉴定8种mAb结合。 几个实验室已经证明 肠道病毒基因组存在于15-25%的患者的心脏组织中, 当感染性病毒不能被检测到时, CVB 3鼠 慢性心肌炎模型将用于确定是否存在病毒性心肌炎。 基因组在心脏组织中持续存在,使用原位转录, 聚合酶链反应 为了了解CVB 3的分子基础, 诱导的心肌炎,高度心肌炎(CVB 3 m)和 将克隆心肌肌萎缩(CVB 30)变体。 相互重组 病毒将通过从感染性病毒中构建杂交基因组来产生。 每个基因组的cDNA分子并评估心肌炎诱导能力 在青春期的老鼠身上。 将构建感染性杂交cDNA分子 与心肌炎相关的核苷酸区域逐渐变小 来产生重组病毒。 相关的核苷酸区域 将对心肌炎进行测序。 几种小鼠株的CVB 3感染 诱导T细胞裂解未感染的靶细胞。 实验将 检测CVB 3 m接种小鼠的T淋巴细胞是否 心肌炎会在体外对可溶性抗原作出反应而增殖 提取自正常鼠心脏/培养的心脏成纤维细胞, 增殖程度是否是心肌炎严重程度的预测指标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Charles J Gauntt其他文献

Charles J Gauntt的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Charles J Gauntt', 18)}}的其他基金

Unique Anti-microbial Rinse to Reduce Oral Inflammation
独特的抗菌冲洗剂可减少口腔炎症
  • 批准号:
    8123164
  • 财政年份:
    2010
  • 资助金额:
    $ 21.55万
  • 项目类别:
Unique Anti-microbial Rinse to Reduce Oral Inflammation
独特的抗菌冲洗剂可减少口腔炎症
  • 批准号:
    7928457
  • 财政年份:
    2010
  • 资助金额:
    $ 21.55万
  • 项目类别:
Unique Anti-microbial Rinse to Reduce Oral Inflammation
独特的抗菌冲洗剂可减少口腔炎症
  • 批准号:
    7671912
  • 财政年份:
    2009
  • 资助金额:
    $ 21.55万
  • 项目类别:
Novel Therapy to Treat Otitis Media
治疗中耳炎的新疗法
  • 批准号:
    7482156
  • 财政年份:
    2008
  • 资助金额:
    $ 21.55万
  • 项目类别:
Non-Toxic Gel to Treat Vulvovaginal Candidiasis
用于治疗外阴阴道念珠菌病的无毒凝胶
  • 批准号:
    7051865
  • 财政年份:
    2006
  • 资助金额:
    $ 21.55万
  • 项目类别:
Novel Topical Treatment for Postherpetic Neuralgia
带状疱疹后神经痛的新型局部治疗
  • 批准号:
    6991051
  • 财政年份:
    2005
  • 资助金额:
    $ 21.55万
  • 项目类别:
Novel Rinse to Treat Oral Candidiasis in Cancer Patients
治疗癌症患者口腔念珠菌病的新型漱口水
  • 批准号:
    6989894
  • 财政年份:
    2005
  • 资助金额:
    $ 21.55万
  • 项目类别:
Novel Skin Barrier to Prevent and Treat Poison Ivy
预防和治疗毒藤的新型皮肤屏障
  • 批准号:
    6833377
  • 财政年份:
    2004
  • 资助金额:
    $ 21.55万
  • 项目类别:
CHRONIC MYOCARDITIS IN A COXSACKIE VIRUS MURINE MODEL
柯萨奇病毒鼠模型中的慢性心肌炎
  • 批准号:
    2222604
  • 财政年份:
    1991
  • 资助金额:
    $ 21.55万
  • 项目类别:
CHRONIC MYOCARDITIS IN A COXSACKIEVIRUS MURINE MODEL
柯萨奇病毒鼠模型中的慢性心肌炎
  • 批准号:
    3365094
  • 财政年份:
    1991
  • 资助金额:
    $ 21.55万
  • 项目类别:

相似海外基金

Immunomodulatory effects of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in mucosal pemphigus vulgaris
桥粒芯糖蛋白 3 嵌合自身抗体受体 T 细胞 (DSG3-CAART) 对粘膜寻常型天疱疮的免疫调节作用
  • 批准号:
    10679911
  • 财政年份:
    2023
  • 资助金额:
    $ 21.55万
  • 项目类别:
Elucidating the immunology of autoantibody formation and function in COVID-19
阐明 COVID-19 中自身抗体形成和功能的免疫学
  • 批准号:
    10639707
  • 财政年份:
    2023
  • 资助金额:
    $ 21.55万
  • 项目类别:
Analysis of abnormal post-translational modifications that promote autoantibody production using high-precision mass spectrometry
使用高精度质谱分析促进自身抗体产生的异常翻译后修饰
  • 批准号:
    23K07915
  • 财政年份:
    2023
  • 资助金额:
    $ 21.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clinical application based on the molecular mechanism of autoantibody production in autoimmunity
基于自身抗体产生的分子机制在自身免疫中的临床应用
  • 批准号:
    23K18361
  • 财政年份:
    2023
  • 资助金额:
    $ 21.55万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Dynamic prediction of type 1 diabetes risk and autoantibody status by a joint model of longitudinal and multistate models
通过纵向和多状态模型的联合模型动态预测1型糖尿病风险和自身抗体状态
  • 批准号:
    10630731
  • 财政年份:
    2023
  • 资助金额:
    $ 21.55万
  • 项目类别:
Novel therapeutic strategies targeting autoantibody-producing RP105-negative B cells by t-SNE method
通过 t-SNE 方法针对产生自身抗体的 RP105 阴性 B 细胞的新治疗策略
  • 批准号:
    23K07910
  • 财政年份:
    2023
  • 资助金额:
    $ 21.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Extracellular vesicle and autoantibody production
细胞外囊泡和自身抗体的产生
  • 批准号:
    23K15265
  • 财政年份:
    2023
  • 资助金额:
    $ 21.55万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of mechanism of autoantibody production in pemphigus in conjunction with information from single cell analysis
结合单细胞分析信息阐明天疱疮自身抗体产生的机制
  • 批准号:
    22K08416
  • 财政年份:
    2022
  • 资助金额:
    $ 21.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Influence of HTLV-1 for autoantibody production system and Th subset
HTLV-1对自身抗体产生系统和Th亚群的影响
  • 批准号:
    22K08552
  • 财政年份:
    2022
  • 资助金额:
    $ 21.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Multi-Platform Homogeneous Multiplexed Autoantibody Assay Based on Liquid Micropiston-Enhanced Time-Resolved Forster Resonance Energy Transfer
基于液体微活塞增强时间分辨福斯特共振能量转移的多平台同质多重自身抗体测定
  • 批准号:
    10576777
  • 财政年份:
    2022
  • 资助金额:
    $ 21.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了